These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

285 related articles for article (PubMed ID: 19304957)

  • 61. Mutations in the bZip region of the CEBPA gene: A novel prognostic factor in patients with acute myeloid leukemia.
    Rivera JC; Nuñez D; Millar E; Ramirez K; Chandía M; Aguayo C
    Int J Lab Hematol; 2023 Dec; 45(6):833-838. PubMed ID: 37621152
    [TBL] [Abstract][Full Text] [Related]  

  • 62. [Investigation and clinical analysis of a family with germline CEBPA mutations in acute myeloid leukemia].
    Zhang JP; Lin D; Wang SC; Li Y; Chen YM; Wang Y; Wei H; Mi YC; Wang JX
    Zhonghua Xue Ye Xue Za Zhi; 2020 Dec; 41(12):1008-1012. PubMed ID: 33445848
    [No Abstract]   [Full Text] [Related]  

  • 63. Prognostic impact of CEBPA mutational subgroups in adult AML.
    Georgi JA; Stasik S; Kramer M; Meggendorfer M; Röllig C; Haferlach T; Valk P; Linch D; Herold T; Duployez N; Taube F; Middeke JM; Platzbecker U; Serve H; Baldus CD; Muller-Tidow C; Haferlach C; Koch S; Berdel WE; Woermann BJ; Krug U; Braess J; Hiddemann W; Spiekermann K; Boertjes EL; Hills RK; Burnett A; Ehninger G; Metzeler K; Rothenberg-Thurley M; Dufour A; Dombret H; Pautas C; Preudhomme C; Fenwarth L; Bornhäuser M; Gale R; Thiede C
    Leukemia; 2024 Feb; 38(2):281-290. PubMed ID: 38228680
    [TBL] [Abstract][Full Text] [Related]  

  • 64. Genotypic and clinical heterogeneity within NCCN favorable-risk acute myeloid leukemia.
    Strickland SA; Shaver AC; Byrne M; Daber RD; Ferrell PB; Head DR; Mohan SR; Mosse CA; Moyo TK; Stricker TP; Vnencak-Jones C; Savona MR; Seegmiller AC
    Leuk Res; 2018 Feb; 65():67-73. PubMed ID: 29310020
    [TBL] [Abstract][Full Text] [Related]  

  • 65. Sporadic and Familial Acute Myeloid Leukemia with CEBPA Mutations.
    Yuan J; He R; Alkhateeb HB
    Curr Hematol Malig Rep; 2023 Oct; 18(5):121-129. PubMed ID: 37261703
    [TBL] [Abstract][Full Text] [Related]  

  • 66. Determination of CEBPA mutations by next generation sequencing in pediatric acute leukemia.
    Akin DF; Oner DA; Kurekci E; Akar N
    Bratisl Lek Listy; 2018; 119(6):366-372. PubMed ID: 29947237
    [TBL] [Abstract][Full Text] [Related]  

  • 67. CEBPA methylation as a prognostic biomarker in patients with de novo acute myeloid leukemia.
    Lin TC; Hou HA; Chou WC; Ou DL; Yu SL; Tien HF; Lin LI
    Leukemia; 2011 Jan; 25(1):32-40. PubMed ID: 20927134
    [TBL] [Abstract][Full Text] [Related]  

  • 68. Mutations in nucleophosmin (NPM1) in acute myeloid leukemia (AML): association with other gene abnormalities and previously established gene expression signatures and their favorable prognostic significance.
    Verhaak RG; Goudswaard CS; van Putten W; Bijl MA; Sanders MA; Hugens W; Uitterlinden AG; Erpelinck CA; Delwel R; Löwenberg B; Valk PJ
    Blood; 2005 Dec; 106(12):3747-54. PubMed ID: 16109776
    [TBL] [Abstract][Full Text] [Related]  

  • 69. K313dup is a recurrent CEBPA mutation in de novo acute myeloid leukemia (AML).
    Carnicer MJ; Lasa A; Buschbeck M; Serrano E; Carricondo M; Brunet S; Aventin A; Sierra J; Di Croce L; Nomdedeu JF
    Ann Hematol; 2008 Oct; 87(10):819-27. PubMed ID: 18587575
    [TBL] [Abstract][Full Text] [Related]  

  • 70. CEBPA mutations in 4708 patients with acute myeloid leukemia: differential impact of bZIP and TAD mutations on outcome.
    Taube F; Georgi JA; Kramer M; Stasik S; Middeke JM; Röllig C; Krug U; Krämer A; Scholl S; Hochhaus A; Brümmendorf TH; Naumann R; Petzold A; Mulet-Lazaro R; Valk PJM; Steffen B; Einsele H; Schaich M; Burchert A; Neubauer A; Schäfer-Eckart K; Schliemann C; Krause SW; Hänel M; Noppeney R; Kaiser U; Baldus CD; Kaufmann M; Herold S; Stölzel F; Sockel K; von Bonin M; Müller-Tidow C; Platzbecker U; Berdel WE; Serve H; Ehninger G; Bornhäuser M; Schetelig J; Thiede C;
    Blood; 2022 Jan; 139(1):87-103. PubMed ID: 34320176
    [TBL] [Abstract][Full Text] [Related]  

  • 71. Prevalence and Prognostic Impact of CEBPA Gene Mutation (Simplified Assay Technique) in Egyptian Acute Myeloid Leukemia Patients with Normal Cytogenetics.
    Said SB; El-Masry SA; Salem DA; Taalab MM; Al-Posttany AS
    Indian J Hematol Blood Transfus; 2016 Dec; 32(4):405-411. PubMed ID: 27812248
    [TBL] [Abstract][Full Text] [Related]  

  • 72. AML with CEBPA mutations: A comparison of ICC and WHO-HAEM5 criteria in patients with 20% or more blasts.
    Zhao D; Zhou Q; Zarif M; Eladl E; Wei C; Atenafu EG; Schuh A; Tierens A; Yeung YWT; Minden MD; Chang H
    Leuk Res; 2023 Nov; 134():107376. PubMed ID: 37690321
    [TBL] [Abstract][Full Text] [Related]  

  • 73. Dysregulated immune and metabolic pathways are associated with poor survival in adult acute myeloid leukemia with CEBPA bZIP in-frame mutations.
    Tien FM; Yao CY; Tsai XC; Lo MY; Chen CY; Lee WH; Lin CC; Kuo YY; Peng YL; Tseng MH; Wu YS; Liu MC; Lin LI; Chuang MK; Ko BS; Yao M; Tang JL; Chou WC; Hou HA; Tien HF
    Blood Cancer J; 2024 Jan; 14(1):15. PubMed ID: 38253683
    [TBL] [Abstract][Full Text] [Related]  

  • 74. Multilineage dysplasia does not influence prognosis in CEBPA-mutated AML, supporting the WHO proposal to classify these patients as a unique entity.
    Bacher U; Schnittger S; Macijewski K; Grossmann V; Kohlmann A; Alpermann T; Kowarsch A; Nadarajah N; Kern W; Haferlach C; Haferlach T
    Blood; 2012 May; 119(20):4719-22. PubMed ID: 22442349
    [TBL] [Abstract][Full Text] [Related]  

  • 75. CSF3R Mutations are frequently associated with abnormalities of RUNX1, CBFB, CEBPA, and NPM1 genes in acute myeloid leukemia.
    Zhang Y; Wang F; Chen X; Zhang Y; Wang M; Liu H; Cao P; Ma X; Wang T; Zhang J; Zhang X; Lu P; Liu H
    Cancer; 2018 Aug; 124(16):3329-3338. PubMed ID: 29932212
    [TBL] [Abstract][Full Text] [Related]  

  • 76.
    Mannelli F; Ponziani V; Bencini S; Bonetti MI; Benelli M; Cutini I; Gianfaldoni G; Scappini B; Pancani F; Piccini M; Rondelli T; Caporale R; Gelli AM; Peruzzi B; Chiarini M; Borlenghi E; Spinelli O; Giupponi D; Zanghì P; Bassan R; Rambaldi A; Rossi G; Bosi A
    Haematologica; 2017 Mar; 102(3):529-540. PubMed ID: 28250006
    [TBL] [Abstract][Full Text] [Related]  

  • 77. A simple cytofluorimetric score may optimize testing for biallelic CEBPA mutations in patients with acute myeloid leukemia.
    Marcolin R; Guolo F; Minetto P; Clavio M; Manconi L; Ballerini F; Carli A; Passannante M; Colombo N; Carminati E; Pugliese G; Tedone E; Contini P; Mangerini R; Kunkl A; Miglino M; Cagnetta A; Cea M; Gobbi M; Lemoli RM
    Leuk Res; 2019 Nov; 86():106223. PubMed ID: 31557597
    [TBL] [Abstract][Full Text] [Related]  

  • 78. Differential Implications of CSF3R Mutations in t(8;21) and CEBPA Double Mutated Acute Myeloid Leukemia.
    Wang B; Wen L; Wang Z; Chen S; Qiu H
    Clin Lymphoma Myeloma Leuk; 2022 Jun; 22(6):393-404. PubMed ID: 34975010
    [TBL] [Abstract][Full Text] [Related]  

  • 79. Single nucleotide polymorphism in the mutational hotspot of WT1 predicts a favorable outcome in patients with cytogenetically normal acute myeloid leukemia.
    Damm F; Heuser M; Morgan M; Yun H; Grosshennig A; Göhring G; Schlegelberger B; Döhner K; Ottmann O; Lübbert M; Heit W; Kanz L; Schlimok G; Raghavachar A; Fiedler W; Kirchner H; Döhner H; Heil G; Ganser A; Krauter J
    J Clin Oncol; 2010 Feb; 28(4):578-85. PubMed ID: 20038731
    [TBL] [Abstract][Full Text] [Related]  

  • 80. Detection of CEBPA double mutants in acute myeloid leukemia using a custom gene expression array.
    van Vliet MH; Burgmer P; de Quartel L; Brand JP; de Best LC; Viëtor H; Löwenberg B; Valk PJ; van Beers EH
    Genet Test Mol Biomarkers; 2013 May; 17(5):395-400. PubMed ID: 23485358
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 15.